

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED

華康生物醫學控股有限公司

(Incorporated in Cayman Islands with limited liability)

(Stock Code: 8622)

VOLUNTARY ANNOUNCEMENT CLARIFICATION OF FALSE OR MISLEADING INFORMATION

This announcement is made by the board (the "**Board**") of directors (the "**Directors**") of Huakang Biomedical Holdings Company Limited (the "**Company**", and together with its subsidiaries, the "**Group**") on a voluntary basis.

The Board has noted certain media reports in the People's Republic of China (the "**PRC**") stating rumors concerning the acquisition (the "**Alleged Acquisition**") of the Company by a company called Jiao Tai Guo Ji* ("**Jiao Tai**"). The Board has also noted that recently certain individuals (the "**Individuals**") visited the Company's premises situated at 1-3/F, Building D, Shenzhen Junxuan, No. 16 Yinkui Road, Kui Xin Community, Kui Chong Office, Dapeng New District, Shenzhen, the PRC claiming to be victims of Jiao Tai.

The Company has inquired the controlling shareholders of the Company and it has been confirmed that such rumours of the Alleged Acquisition are untrue and unfounded. Furthermore, the Board hereby clarifies and confirms that, as at the date of this announcement, the Company is unrelated to (i) Jiao Tai and (ii) the claims of the Individuals.

The Company reserves all rights to pursue appropriate action against Jiao Tai and/or such person(s) for concocting and spreading such unfounded information regarding the Group.

Shareholders and potential investors of the Company are urged to exercise caution when dealing in the shares of the Company.

By Order of the Board
Huakang Biomedical Holdings Company Limited
Zhang Shuguang
Chairman and Executive Director

Hong Kong, 31 January 2022

As at the date of this announcement, the Executive Directors are Mr. Zhang Shuguang, Mr. Zhang Chunguang, Mr. Poon Lai Yin Michael and Mr. He Jiaming; and the Independent Non-executive Directors are Dr. Chow Kwok Fai Joseph, Dr. Cheng Faat Ting Gary and Mr. Chan Kin Sang.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Company Announcements” page of the GEM website at www.hkgem.com for at least seven days from the date of publication and on the Company’s website at www.huakangbiomedical.com.

** For identification purpose only*